6 ring atoms, wherein the heterocyclic group comprises a heteroatom selected from N, O and S, and wherein the carbocyclic or heterocyclic group may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO_2, (f) CF_3, (g) C_{1-4} alkyl, (h) SCH_3, (i) $NHCOCH_3$, (j) $N(R^6)(R^8)$ wherein R^6 and R^8 are the same or different and each represents H or C_{1-4} alkyl, (k) OR^{10} wherein R^{10} represents a saturated or unsaturated C_{1-6} straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO_2 and CF_3, and (l) $-OCOR^{11}$ wherein R^{11} represents a saturated or unsaturated C_{1-6} straight or branched hydrocarbyl group or a phenyl group;

B' cont'd

R represents OH, OR^{10} or $OCOR^{11}$ wherein R^{10} and R^{11} are as defined above; and R^1 represents H or a C_{1-6} straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO_2 and CF_3;

with the proviso that:

(i) when R^1 is CH_3 and Ris OH, then Ar cannot be 4-pyridyl, 4-methylphenyl, 3-nitrophenyl, 3-methoxy-4-ethoxyphenyl, 3-methoxy-4-n-butoxyphenyl, 4-(N,N-dimethylamino)phenyl, 2-hydroxy-3,5-dibromophenyl, 2-hydroxy-5-methylphenyl, 4-chlorophenyl, phenyl, 3-methoxyphenyl,4-methoxyphenyl,or 3,4-dimethoxyphenyl;

(ii) when R^1 is CH_3 and R is $OCOCH_3$, the group, then Ar cannot be phenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 4-(N,N-dimethylamino)phenyl, 3-methoxy-4-acetoxyphenyl, 3,4,5-trimethoxyphenyl, or 2-chlorophenyl;

(iii) when R^1 is phenyl or H and R is OCH_3 or OH, then Ar cannot be 4-methoxyphenyl; and

(iv) when R^1 is CH_3 and Ris OCH_3 or OH, then Ar cannot be 4-methoxyphenyl or 3,4-dimethoxyphenyl.

B2

48. (Amended) A method of treating cancer in a patient comprising administering to the patient a compound of formula:



or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents: a substituted or unsubstituted, aromatic or non-aromatic, carbocyclic or heterocyclic group having from 5 to 10 ring atoms or two rings with each ring containing 5 or 6 ring atoms, wherein the heterocyclic group comprises a heteroatom selected from N, O and S, and wherein the carbocyclic or heterocyclic group may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO_2, (f) CF_3, (g) C_{1-4} alkyl, (h) SCH_3, (i) $NHCOCH_3$, (j) $N(R^6)(R^8)$ wherein R^6 and R^8 are the same or different and each represents H or C_{1-4} alkyl, (k) OR^{10} wherein R^{10} represents a saturated or unsaturated C_{1-6} straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO_2 and CF_3, and (l) $-OCOR^{11}$ wherein R^{11} represents a saturated or unsaturated C_{1-6} straight or branched hydrocarbyl group or a phenyl group;

B2 Cont

R represents OH, OR^{10} or $OCOR^{11}$ wherein R^{10} and R^{11} are as defined above; and R^1 represents H or a C_{1-6} straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO_2 and CF_3.

49. (Amended) A method of treating or preventing neoplasms in a patient comprising administering to the patient a compound of formula:



or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents: a substituted or unsubstituted, aromatic or non-aromatic, carbocyclic or heterocyclic group having from 5 to 10 ring atoms or two rings with each ring containing 5 or 6 ring atoms, wherein the heterocyclic group comprises a heteroatom selected from N, O and S, and wherein the carbocyclic or heterocyclic group may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO_2, (f) CF_3, (g) C_{1-4} alkyl, (h) SCH_3, (i) $NHCOCH_3$, (j) $N(R^6)(R^8)$ wherein R^6 and R^8 are the same or different and each represents H or C_{1-4} alkyl, (k) OR^{10} wherein R^{10} represents a saturated or unsaturated C_{1-6} straight or branched hydrocarbyl group which may be

B2 Contd

unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO_2 and CF_3, and (I) -$OCOR^{11}$ wherein R^{11} represents a saturated or unsaturated C_{1-6} straight or branched hydrocarbyl group or a phenyl group;

R represents OH, OR^{10} or $OCOR^{11}$ wherein R^{10} and R^{11} are as defined above; and R^1 represents H or a C_{1-6} straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO_2 and CF_3.

B3

56. (Amended) A [The] pharmaceutical composition comprising:

(A) a compound of Formula (I):



(I)

or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents: a substituted or unsubstituted, aromatic or non-aromatic, carbocyclic or heterocyclic group having from 5 to 10 ring atoms or two rings with each ring containing 5 or 6 ring atoms, wherein the heterocyclic group comprises a heteroatom selected from N, O and S, and wherein the carbocyclic or heterocyclic group may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO_2, (f) CF_3, (g) C_{1-4} alkyl, (h) SCH_3, (i) $NHCOCH_3$, (j) $N(R^6)(R^8)$ wherein R^6 and R^8 are the same or different and each represents H or C_{1-4} alkyl, (k) OR^{10} wherein R^{10} represents a saturated or unsaturated C_{1-6} straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO_2 and CF_3, and (I) -$OCOR^{11}$ wherein R^{11} represents a saturated or unsaturated C_{1-6} straight or branched hydrocarbyl group or a phenyl group;

R represents OH, OR^{10} or $OCOR^{11}$ wherein R^{10} and R^{11} are as defined above; and R^1 represents H or a C_{1-6} straight or branched hydrocarbyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO_2 and CF_3; and

(B) one or more antineoplastic agents.

A complete listing of the currently pending claims is provided in Appendix B for the Examiners convenience.